5 Coronavirus Vaccines With Huge Operation Warp Speed Deals
The U.S. government has promised $7.9 billion to secure hundreds of millions of doses of these SARS-CoV-2 vaccine candidates.
Cory Renauer(TMFang4apples)Aug 1, 2020 at 6:33AMAuthor Bio
Operation Warp Speed (OWS), the Trump administration’s bold effort to deliver at least 300 million doses of a safe and effective coronavirus vaccine by January, took another expensive step forward. On Friday, Sanofi (NASDAQ:SNY) and GlaxoSmithKline (NYSE:GSK) signed a vaccine-supply deal with the U.S. government worth up to $2.1 billion to help the collaboration partners scale up manufacturing of a vaccine candidate — before there are clinical-trial results that prove it safely prevents SARS-CoV-2, the virus that causes COVID-19, from spreading.
Bottomless expense accounts have allowed the leading vaccine candidates to advance at top speed. Here’s a quick rundown to help you keep tabs on the top five programs and the funds that are pushing them forward.
|Company (Symbol)||OWS Funding||Phase 3 Start Date|
|Sanofi and GlaxoSmithKline||$2.1 billion||End of 2020|
|BioNTech SE (NASDAQ:BNTX) and Pfizer (NYSE:PFE)||$2 billion||July 27, 2020|
|Novavax (NASDAQ:NVAX)||$1.6 billion||Fall 2020|
|AstraZeneca (NYSE:AZN)||$1.2 billion||June 20, 2020|
|Moderna (NASDAQ:MRNA)||$955 million||July 27, 2020|
DATA SOURCE: COMPANY PRESS RELEASES.
Who needs a name?
Sanofi and GlaxoSmithKline are committed to developing a coronavirus vaccine candidate at top speed but haven’t yet bothered to give their protein-based vaccine candidate a name. Sanofi will provide the partnership with a protein that mimics part of SARS-CoV-2, and GlaxoSmithKline will contribute an adjuvant designed to spark a stronger immune response to Sanofi’s protein.